Regulation of fibrillins and modulators of TGF β in fetal bovine and human ovaries

Nicole A Bastian¹, Rosemary A Bayne², Katja Hummitzsch¹, Nicholas Hatzirodos¹, Wendy M Bonner¹, Monica D Hartanti¹, Helen F Irving-Rodgers^{1,3}, Richard A Anderson² and Raymond J Rodgers¹

¹Discipline of Obstetrics and Gynaecology, School of Medicine, Robinson Research Institute, The University of Adelaide, Adelaide, South Australia, Australia, ²Medical Research Council Centre for Reproductive Health, University of Edinburgh, Queen's Medical Research Institute, Edinburgh, UK and ³School of Medical Science, Griffith University, Gold Coast Campus, Southport, Queensland, Australia

Correspondence should be addressed to R J Rodgers; Email: ray.rodgers@adelaide.edu.au

Abstract

Fibrillins 1–3 are stromal extracellular matrix proteins that play important roles in regulating TGF β activity, which stimulates fibroblasts to proliferate and synthesize collagen. In the developing ovary, the action of stroma is initially necessary for the formation of ovigerous cords and subsequently for the formation of follicles and the surface epithelium of the ovary. *FBN3* is highly expressed only in early ovarian development and then it declines. In contrast, *FBN1* and 2 are upregulated in later ovarian development. We examined the expression of *FBN1–3* in bovine and human fetal ovaries. We used cell dispersion and monolayer culture, cell passaging and tissue culture. Cells were treated with growth factors, hormones or inhibitors to assess the regulation of expression of *FBN1–3*. When bovine fetal ovarian tissue was cultured, *FBN3* expression declined significantly. Treatment with TGF β -1 increased *FBN1* and *FBN2* expression in bovine fibroblasts, but did not affect *FBN3* expression. Additionally, in cultures of human fetal ovarian fibroblasts (9–17 weeks gestational age), the expression of *FBN1* and *FBN2* increased with passage, whereas *FBN3* dramatically decreased. Treatment with activin A and a TGF β family signaling inhibitor, SB431542, differentially regulated the expression of a range of modulators of TGF β signaling and of other growth factors in cultured human fetal ovarian fibroblasts suggesting that TGF β signaling is differentially involved in the regulation of ovarian fibroblasts. Additionally, since the changes in *FBN1–3* expression that occur *in vitro* are those that occur with increasing gestational age *in vivo*, we suggest that the fetal ovarian fibroblasts mature *in vitro*.

Reproduction (2016) **152** 127–137

Introduction

Fibroblasts or stromal cells are of mesenchymal origin (Wong *et al.* 2007) and are a major cell type present in the stroma of many organs (Birchmeier & Birchmeier 1993). They play an important role in the production and deposition of collagen in tissues (Varga *et al.* 1987, Christner & Ayitey 2006) and ensure proper organ development and function (Saxen & Sariola 1987, Birchmeier & Birchmeier 1993). Perturbations within the stroma can result in defects in the functions of organs such as pulmonary fibrosis (Rock *et al.* 2011), cardiac fibrosis (Chen *et al.* 2000), renal fibrosis (Ito *et al.* 1998) and polycystic ovary syndrome (PCOS) (Hughesdon 1982).

Fibroblasts are activated by a profibrotic cytokine, TGF β (Roberts *et al.* 1986, Chen *et al.* 2000, Raja-Khan *et al.* 2014). There are three TGF β s secreted as inactive latent homodimeric complexes of precursor molecules each consisting of a signal peptide, a latency-associated peptide (LAP) and a mature peptide (Saharinen *et al.* 1999). These LAPs form covalent disulfide bonds with

other chaperone proteins called latent TGF β -binding proteins (LTBPs) (Saharinen *et al.* 1999), specifically LTBP1, LTBP3 and LTBP4 (Isogai *et al.* 2003). LTBPs also play a role in regulating the secretion of latent TGF β from cells and targeting latent TGF β to the extracellular matrix (ECM) (Taipale *et al.* 1994, Isogai *et al.* 2003), where glycoproteins called fibrillins are present.

Fibrillins are major structural components in stromal ECM (Ramirez & Pereira 1999). In addition to their structural function, they regulate growth factor/cytokine activity by binding LTBPs 1 to 4 (Isogai *et al.* 2003, Zilberberg *et al.* 2012) and thus sequestering latent TGF β in the ECM (Chaudhry *et al.* 2007). This is important for the regulation of TGF β activation and bioavailability in the ECM (Saharinen *et al.* 1999, Chaudhry *et al.* 2007) and hence for stromal fibroblast function. TGF β is only released from the ECM and activated via proteolytic cleavage (Saharinen *et al.* 1999). Activated TGF β can then activate fibroblasts to proliferate and synthesize ECM proteins such as collagens and

fibronectin (Fine & Goldstein 1987, Varga *et al.* 1987, Leask & Abraham 2004). In 2004, another member of the fibrillin family, fibrillin 3, was discovered (Corson *et al.* 2004). The expression of the *FBN3* gene was shown to be significantly higher in fetal compared with adult tissues of the same organs (Corson *et al.* 2004, Sabatier *et al.* 2010, Hatzirodos *et al.* 2011). Furthermore, in addition to humans, *FBN3* is expressed in cows, sheep and chickens, but not in rodents (Corson *et al.* 2004).

Recent studies have proposed a new model of mammalian ovarian development, which emphasizes the importance of stromal penetration and expansion as crucial processes in the developing fetal bovine and human ovaries (Hummitzsch *et al.* 2013, 2015, Heeren *et al.* 2015). The stromal tissue first penetrates the developing ovary from the mesonephros, and while doing so, it subdivides and thus partitions the oogonia and the precursor gonadal-ridge epithelial (GREL) cells of the ovary into ovigerous cords. It then segregates the ovigerous cords into smaller groups of cells thus contributing to the formation of follicles. Finally, it penetrates to just below the surface of the ovary before spreading laterally, thus isolating some GREL cells at the surface of the ovary. These GREL cells then begin to form an epithelium on the surface. Throughout ovary development, the stroma expresses fibrillin genes, but different ones at different times. In the bovine and human, *FBN1* is expressed during fetal ovarian development and increases significantly in the adult ovary (Hatzirodos *et al.* 2011). *FBN2* is also expressed in fetal ovaries, but declines in the later stages of bovine fetal ovarian development and increases in the adult bovine ovary. In humans, *FBN2* is expressed during fetal ovarian development but is very low in the adult ovary (Hatzirodos *et al.* 2011). *FBN3* is highly expressed in the early bovine and human fetal ovary; however, its expression declines and is undetectable in adult bovine and human ovaries (Hatzirodos *et al.* 2011). Histochemical localization of fibrillin 3 revealed an extensive network of fibrillin 3 fibers in the stromal compartment, as it penetrates between ovigerous cords in fetal bovine and human ovaries (Hatzirodos *et al.* 2011, Hummitzsch *et al.* 2013). These findings suggest that fibrillin 3 plays a crucial role in the fetal ovary during early ovary development, when stromal tissue is expanding from the mesonephros into the developing ovary (Hatzirodos *et al.* 2011, Hummitzsch *et al.* 2013), but as development progresses, fibrillin 1 in particular becomes more important.

Although the stromal matrix protein fibrillin-3 appears to have an important role early in fetal development, in contrast to all other fibrillins, LTBP and TGF β molecules, there is very little knowledge about its regulation or function. A recent study by Davis *et al.* (2014) identified the promoters of the human fibrillin genes and the transcription factors that bind to these promoters (Davis *et al.* 2014). This study was heavily biased to adult tissues

present in the FANTOM database at that time, thus limiting the information about the promoter of *FBN3* and identification of potential transcription factor-binding motifs present within this promoter. Interestingly, it was found that the transcription factor-binding motifs in the *FBN3* promoter do not overlap with those of the other two fibrillin genes (Davis *et al.* 2014). This would be consistent with the differential expression of the fibrillin genes seen in ovaries (Hatzirodos *et al.* 2011).

The *FBN3* gene may be associated with the occurrence of PCOS (Urbanek *et al.* 2007). The PCOS ovary phenotype has the hallmarks of increased TGF β activity with expanded stroma and collagen deposition (Hughesdon 1982). Additionally, the behavior of the specialized stromal thecal cells is altered in polycystic ovary syndrome, with increased steroidogenic activity (Nelson *et al.* 1999, Polla *et al.* 2003). Thus, aberrant *FBN3* activity during fetal development could be related to the altered stroma phenotype in the PCOS ovary (Hatzirodos *et al.* 2011, Raja-Khan *et al.* 2014). In this study, our goals were to determine the factors that affect *FBN1–3* expression in human and bovine fetal ovaries.

Materials and methods

Bovine fetal tissues

Bovine fetal ovaries from a range of gestational ages were collected from fetuses of *Bos taurus* cows from a local abattoir (Thomas Foods International, Murray Bridge, SA, Australia). The crown–rump length of the fetuses was measured to determine the approximate ages of fetuses (Russe 1983), and the fetal ovaries were transported on ice in Hank's balanced salt solution containing Mg²⁺ and Ca²⁺ (HBSS^{+/+}; Sigma-Aldrich) to the laboratory. The connective tissue surrounding the fetal ovaries was removed and a small portion of the ovaries was excised and frozen at -80°C for subsequent RNA extraction. The ovaries were rinsed once in 70% ethanol and twice in HBSS^{+/+} and then dissected into small pieces and minced with a scalpel. The fetal ovaries were digested in 3–5 mL of 1 mg/mL collagenase type I (GIBCO/ Life Technologies Australia Pty Ltd) in HBSS^{+/+} at 37°C shaking at 150 r.p.m. The durations of digestion for the fetal ovaries depended on the crown–rump lengths of the fetuses. After the first digestion, the samples were centrifuged at 300g for 5 min and the supernatant was removed. The samples were then digested in 2 mL of 0.025% trypsin/EDTA (GIBCO/ Life Technologies) in Hank's balanced salt solution without Mg²⁺ and Ca²⁺ (HBSS^{-/-}; Sigma-Aldrich) for 5 min at 37°C at 150 r.p.m. After centrifugation at 300g for 5 min, the cell pellets were resuspended in DMEM/F12 medium containing 5% FCS, 1% penicillin and streptomycin sulfate, and 0.1% fungizone (all GIBCO/ Life Technologies) and the cells were dispersed further by pipetting up and down. The fetal fibroblasts were cultured in 6 well plates or 10 cm Petri dishes at 38.5°C and 5% CO₂ until confluence. Once the fetal fibroblast cultures were confluent, the cells were detached by treatment with 0.25% trypsin/EDTA, the total number of viable cells was estimated with the trypan blue method using a hemocytometer and the cells subsequently stored in liquid nitrogen for later use.

Human fetal tissues

Morphologically normal human fetal ovaries (9–17 weeks gestation) were obtained following medical termination of pregnancy. Maternal consent was obtained and the study was approved by the Lothian Research Ethics Committee (ref 08/S1101/1). Gestational age of the fetuses was determined by ultrasound scan and by direct measurement of the fetal foot length. Extraneous tissue was removed from ovaries in HBSS (GIBCO/Life Technologies). Ovaries were manually dispersed under a dissection microscope using 19 gauge needles in 500 µL of 10 mg/mL Collagenase IV (Sigma) in HBSS. The tissue/collagenase suspension was incubated in a thermomixer at 37°C, shaking at 1000 r.p.m. for 10 min and pipetted up and down to ensure complete disaggregation of the tissue. Fifty microliters of DNase I (7 mg/mL HBSS; Sigma) were added to the suspension and incubated for a further 5 min, shaking at 37°C. The single-cell suspension was then centrifuged at 600g for 5 min and the cell pellet was washed twice with 1 mL HBSS, centrifuging between each wash. The cell pellet was then resuspended in 1 mL DMEM (without phenol red) (Gibco/Life Technologies) supplemented with 10% FCS, 2 mM L-glutamine, 1X MEM nonessential amino acids (NEAA; all Gibco/Life Technologies) and 1X penicillin/streptomycin/amphotericin (Gibco/Life Technologies). The cell suspension was filtered through a 70 µm filter and the resulting filtrate centrifuged. The cell pellet was resuspended in 1.2 mL culture medium. Two hundred microliters of the initial cell suspension were transferred to a separate fresh 1.5 mL tube and centrifuged.

The cell pellet was washed in 1X phosphate-buffered saline (PBS), resuspended in 350 µL buffer RLT (Qiagen) with 2-mercapthoethanol (Sigma-Aldrich) and stored at –80°C for RNA isolation (T_0). The remaining cells were cultured in 2 wells of a 12 well plate at 37°C and 5% CO₂ overnight. After 13–17 h, the cells were washed twice with culture medium and these washes were collected and centrifuged. The pellet was washed with PBS, resuspended in 350 µL buffer RLT plus 2-mercapthoethanol and stored at –80°C for RNA isolation (S_0). Fresh culture medium was added to each well and the cells were cultured further until confluence (P0 culture). Once the cell cultures were confluent, the cells were detached through trypsinisation. An aliquot of the cells was collected for RNA extraction. The remaining cells were passaged into either a 6 well plate or 25 cm² tissue culture flask. Passaging of cells and freezing down aliquots of cells in Bambanker (Anachem, Luton, Beds, UK), and freezing the medium were continued for several passages.

Screening for possible regulators of FBN3 expression in cultured bovine fetal fibroblasts

Bovine fetal fibroblasts ($n=5$ from weeks 13, 14, 17, 19 and 33 of gestation) previously stored in liquid nitrogen were thawed and 30,000 cells/well were seeded in 24 well plates in DMEM/F12 medium containing 5% FCS, 1% penicillin and streptomycin sulfate and 0.1% fungizone, and incubated for 24 h at 38.5°C and 5% CO₂ until 60–70% confluence.

Table 1 Treatments for cultured bovine fetal ovarian fibroblasts.

Category	Treatments	Concentration	Distributor
Hormones	Dihydroxytestosterone	100 ng/mL	Sigma-Aldrich
	Estradiol	100 ng/mL	Sigma-Aldrich
	Progesterone	100 ng/mL	Sigma-Aldrich
	Testosterone	100 ng/mL	Sigma-Aldrich
	Prolactin	1 µg/mL	National Institute of Diabetes and Digestive and Kidney Diseases – National Institutes of Health
	Relaxin	16.7 nM	From Dr Ross Bathgate – University of Melbourne, Australia
	Insulin-like protein 3	100 ng/mL	From Dr Ross Bathgate – University of Melbourne, Australia
	Müllerian-inhibiting substance	10 ng/mL	Biogen Idec Australia Pty Ltd, North Ryde, NSW, Australia
	Insulin-like growth factor 1	30 ng/mL	GroPep Bioreagents Pty Ltd, Thebarton, SA, Australia
Prostaglandins	Prostaglandin E2	1 µM	Upjohn Company, Kalamazoo, MI, USA
	Prostaglandin F2α	1 µM	Upjohn Company, Kalamazoo, MI, USA
Cytokines	Interleukin 1 beta	50 ng/mL	R&D Systems, distributed by Bio-Scientific Pty Ltd, Gympie, NSW, Australia
Stimulators	Tumor necrosis factor	10 ng/mL	R&D Systems
	Forskolin	4.1 µg/mL	Sigma-Aldrich
Vitamin	Dibutyryl adenosine cyclic monophosphate	1 mM	Sigma-Aldrich
	Retinoic acid	3 µg/mL	Sigma-Aldrich
Growth factors	Activin A	100 ng/mL	R&D Systems
	Basic fibroblast growth factor	100 ng/mL	Roche Australia Pty Ltd, Thebarton, SA, Australia
	Bone morphogenetic protein 6	100 ng/mL	R&D Systems
	Epidermal growth factor	10 ng/mL	Boehringer Ingelheim Pty Ltd, North Ryde, NSW, Australia
	Fibroblast growth factor 7	10 ng/mL	R&D Systems
	Fibroblast growth factor 9	30 ng/mL	R&D Systems
	Platelet-derived growth factor	10 ng/mL	R&D Systems
	Bone morphogenetic protein 15	100 ng/mL	R&D Systems
	Connective tissue growth factor	25 ng/mL	Invitrogen/Life Technologies
	Stem cell factor	100 ng/mL	R&D Systems
	Transforming growth factor beta 1	10 ng/mL	R&D Systems
	Vascular endothelial growth factor	10 ng/mL	R&D Systems
	Glial-derived factor 9	100 ng/mL	R&D Systems
	Glial-cell-derived neurotrophic factor	100 ng/mL	R&D Systems
	Leukemia inhibitory factor	10 ³ U/mL	Sigma-Aldrich

The wells were washed with 1X PBS, and subsequently different chemical treatments were added. All treatments were prepared in DMEM/F12 medium containing 1% FCS, 1% penicillin and streptomycin sulfate, and 0.1% fungizone. After 18h, the cells were harvested for RNA extraction by lysis in 500 µL TRIzol (Ambion/Life Technologies) each and stored at -80°C . To limit the number of samples for the qRT-PCR, the treatments were used at concentrations previously reported in the literature instead of dose-response experiments for each of the 31 agents (Table 1).

Treatment of bovine fibroblast cultures with TGFβ1 and TGFβ inhibitor SB431542

Bovine fetal fibroblasts ($n=5$ for weeks 9–15 in the first trimester, $n=6$ for weeks 19–26 in the second trimester) were seeded at 30,000 cells/well in 24 well plates in DMEM/F12 medium containing 5% FCS, 1% penicillin and streptomycin sulfate and 0.1% fungizone, and incubated for 24h at 38.5°C and 5% CO_2 until 60–70% confluence. After 24h, the wells were washed with 1X PBS and immediately treated with 5 ng/mL or 20 ng/mL TGFβ-1 with or without the TGFβ inhibitor SB431542 (10 µM, dissolved in DMSO, Sigma-Aldrich) in DMEM/F12 medium containing 1% FCS, 1% penicillin and streptomycin sulfate and 0.1% fungizone. DMSO (0.78%), the vehicle for SB431542, was added to the control wells and the wells treated with TGFβ-1 alone. After 18h, the cells were harvested for RNA.

Culture of bovine ovarian tissue slices

Bovine fetal ovaries ($n=4$ 12–18 weeks) were excised into two portions; one portion was stored at -80°C (0h tissue) for subsequent RNA extraction and the second portion was cultured in DMEM/F12 medium containing 5% FCS, 1% penicillin and streptomycin sulfate and 0.1% fungizone, and incubated for 24h at 38.5°C and 5% CO_2 . After 24h, the ovarian tissue slices were collected and frozen at -80°C for RNA extraction.

Treatment of human fetal ovarian fibroblasts with TGFβ-1, activin A and SB431542

Human fetal ovarian fibroblasts ($n=3$, 15–17 weeks gestation) were cultured in 75 cm² tissue culture flasks until subconfluence. Cells were then seeded in culture medium in 6 or 12 well plates at 37°C for 7h. Once 70% confluent, the cells were washed and serum-starved overnight in culture medium containing only 1% FCS. The next day, the medium was replaced with fresh culture medium containing 1% FCS and the relevant treatments or vehicle; 5 ng/mL TGFβ-1, 100 ng/mL activin A and 10 µM SB431542. The cells were incubated at 37°C for 24h and then harvested for RNA extraction.

RNA extraction and cDNA synthesis

For our bovine study, the ovarian tissue samples previously frozen were homogenized in 1 mL TRIzol with 0.5 g ceramic beads in homogenization tubes using the Mo Bio PowerLyzer

24 (Mo Bio Laboratories Inc, Carlsbad, CA, USA). The cells previously harvested for RNA and the homogenized tissue samples underwent further treatment for RNA extraction as per manufacturer's instructions (Ambion/Life Technologies). Using a Nanodrop spectrophotometer (NanoDrop 1000 3.7.1, Thermo Fisher Scientific), the RNA concentrations were determined based on the 260λ (wavelength) absorbance. All samples had a 260/280λ absorbance ratio >1.8 indicating sufficient RNA purity for analysis. Two hundred nanograms of each DNase-treated RNA underwent cDNA synthesis as described in a previous study (Matti *et al.* 2010).

For the human samples, RNA was extracted from cells using the RNeasy Micro Kit (Qiagen) with on-column DNase I digestion as per manufacturer's instructions. After quantification on a Nanodrop spectrophotometer, reverse transcription was carried out using 200 ng RNA/reaction with the Maxima First Strand cDNA synthesis kit (Thermo Fisher Scientific).

Quantitative real-time PCR

Quantitative real-time PCR of the bovine samples for the target genes *FBN1*, *FBN2* and *FBN3* and the housekeeping gene *18S* was performed using a Rotor-Gene 6000 series 1.7 thermal cycler (Corbett Life Science, Concord, NSW, Australia). cDNA dilutions were amplified in 10 µL reactions containing 5 µL Power SYBR Green PCR Master Mix (Applied Biosystems/Life Technologies), 0.1 µL each of reverse and forward primers (Geneworks; Table 2) respectively for the genes of interest, 1 µL of the 1:100 cDNA dilution (for the housekeeping gene *18S*) or 1:10 cDNA dilution (for *FBN1*, *FBN2*, *FBN3*) and 3.8 µL DEPC-treated water. PCR amplification of the cDNA samples was carried out in duplicates at 95°C for 15s, followed by 60°C for 60s for 40 cycles. The Rotor-Gene 6000 software (Q Series, Qiagen) was used to determine the cycle threshold (Ct) values at a threshold of 0.05 normalized fluorescence units. Gene expression was determined by the mean of $2^{-\Delta\text{Ct}}$, where ΔCt represents the target gene Ct – *18S* Ct. The standard error of the mean ($\pm\text{S.E.M.}$) for the power calculation was determined accordingly: $2^{(-\Delta\text{Ct} + \text{SEM}\Delta\text{Ct})} - 2^{-\Delta\text{Ct}} / 2^{(-\Delta\text{Ct} - \text{SEM}\Delta\text{Ct})} - 2^{-\Delta\text{Ct}}$.

Gene expression in human fetal ovaries and ovarian cell cultures was analyzed by qRT-PCR using the ABI7900 Fast system with SDS2.4 software (Life Technologies) and Brilliant III SYBR Green Master Mix (Agilent Technologies), with melt curve analysis as described previously (Bayne *et al.* 2015). Primers used for the qRT-PCR are shown in Table 2.

Statistical analyses

All statistical calculations were performed using Microsoft Office Excel 2010 (Microsoft) and GraphPad Prism version 6.00 (GraphPad Software). For the treatment experiments on bovine and human samples, statistical comparisons of the ΔCt data between the untreated control and the treatments for each fetal fibroblast sample were conducted using log transformed data where appropriate by ANOVA with Dunnett's *post hoc* test and a value of $P<0.05$ was considered significant. For the bovine ovarian tissue culture experiment, statistical comparisons of the ΔCt data between the 0h tissue and the 24h cultured tissue for each fetal ovary

Table 2 List of genes and primers used for qRT-PCR.

Gene name	Gene symbol	Species specificity	Location of amplicon	Forward primer sequence (5'→3')	Reverse primer sequence (5'→3')	GenBank accession number
18S rRNA	18S	Bovine	445–535	AGAAACGGCTACCACATCCAA	CCTGTATTGTTATTTTCGTCACCTACC	AM711877.1
Fibrillin 1	FBN1	Human	280–384	GGGATGGATTGTTTCGAGGC	CATCACTGCAGCTACCTCCATT	NM_174053.2
Fibrillin 2	FBN2	Bovine	1697–1758	GGACTCTCAACAGCAAGCATG	ACAAAGAACCCATCTCGGATG	NM_001278588.1
Fibrillin 3	FBN3	Bovine	8011–8090	GCCAGAGCCTCGCTAGATGT	CTGCCCTCAGTGTCTTTC	XM_002688838.2
60S ribosomal protein L32	RPL32	Human	34–186	CATCTCTCTCGGATCA	AACCCCTGTGTCAATGCCTC	AK311909.1
Fibrillin 1	FBN1	Human	1822–1882	AGCACACTACGCGGACA	AGATCCGGCATCTGTAAACA	BC146854
Fibrillin 2	FBN2	Human	7545–7646	TCCAGTCAAGTCTCTCAGGCAC	TGGACTACTGTGTCCTATT	NM_001999
Fibrillin 3	FBN3	Human	1716–1787	TGGCGGCCTACTGCAT	TGGTACAGTGGCCGTTCC	NM_032447
Latent TGFβ-binding protein 1	LTBP1	Human	3195–3322	CCCCAATGTCAGCAACAAGA	AACCTTCCCTTTGGGACACA	BC130289
Latent TGFβ-binding protein 2	LTBP2	Human	3276–3382	CAGGAAGGACACTGCCAAGA	CCTCAGAGCCAGACAAGTGTA	NM_000428
Latent TGFβ-binding protein 3	LTBP3	Human	2882–2962	TCTCACTGACCGGAGTTCC	TGCCGTAGTTGACGATGTTGT	NM_001130144.1
Latent TGFβ-binding protein 4	LTBP4	Human	4003–4068	CGCTGCTCTCAACGA	CCCACTCTCGCCAGCAC	NM_001042544.1
TGFβ1	TGFB1	Human	1191–1253	CACCCGCGTGCTAATGG	TGTGTACTCTGCTTGAACCTGTCTCAT	NM_000660.3
TGFβ2	TGFB2	Human	1209–1287	AAAGCAGAGTGCCTGAACA	AGCGTGGGTTGGAGATG	NM_001135599.1
TGFβ3	TGFB3	Human	1164–1264	AAGAAATCCATAATTCGACATGATC	CACATTGAAGCGGAAACCTT	NM_003239.2
TGFβ-induced	TGFB1	Human	1274–1533	CATCCAGACTCAGCAAGA	GAGTTCCAGGGTCTGTCCA	NM_000358.2
Androgen receptor	AR	Human	763–961	GACAGATGGCTGCTATTCA	GGAGCCATCCAAACTCTGA	NM_001011645.2
Activin beta A subunit	INHBA	Human	530–652	AAGTCGGGAGAACGGGTATGTGG	TCTTCTGGCTTCTCTGACTCG	NM_002192.2
HtrA serine peptidase 1	HTRA1	Human	1054–1119	TCCGCACTCAGACATGGAC	GGCTCTCCGATTTTCCATAG	NM_002775.4
Brain-derived neurotrophic factor	BDNF	Human	531–752	ACAATAAGGACGCAGACTT	TGCAGTCTTTTGTCTGCGG	X91251.1

Figure 1 Expression of *FBN3* in bovine fetal fibroblasts from different gestational ages cultured in the presence of 31 different chemical agents grouped as indicated (A to H) for 18 h. The data are shown as mean $\pm$ S.E.M. of fold change in *FBN3* expression relative to the untreated control ($n=5$ ovaries, each from 13, 14, 17, 19 and 33 weeks of gestation, respectively).

sample were conducted by unpaired *T*-tests and a value of $P<0.05$ was considered significant.

Results

Screening for possible regulators of *FBN3*

To identify possible regulators of *FBN3*, we treated bovine fetal ovarian fibroblasts ($n=5$ ovaries, each from 13, 14, 17, 19 and 33 weeks of gestation) with 31 different reagents (Table 1) for 18 h and observed their effects on *FBN3* expression (Fig. 1). The range of treatments used included cAMP regulators, growth factors, steroid hormones, peptide hormones, prostaglandins and

cytokines, previously shown to play roles in adult ovarian function, such as cell proliferation and extracellular matrix production. No substantial effects were seen in any individual culture and the data were therefore combined across the gestational ages for statistical analyses, which showed that there were no significant differences in *FBN3* expression between the control and any of the treated cultures. Furthermore, we also observed that the expression of *FBN3* in these cultures was very low.

Treatment of bovine fetal fibroblasts with TGF β -1 and TGF β -inhibitor SB431542

A partial dose-response experiment was carried out using 5 or 20 ng/mL TGF β -1 with or without the TGF β -signaling inhibitor SB431542, which selectively inhibits the TGF β superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5 and ALK7 (Inman *et al.* 2002a), using fetal ovarian fibroblast cultures ($n=5$ ovaries from weeks 9–15 in first trimester; $n=6$ ovaries from weeks 19–26 in the second trimester). Gene expression analyses showed that the expression of *FBN1* in fetal ovarian fibroblasts from 9–15 weeks of gestation was not significantly

Figure 2 Expression of *FBN1–3* in bovine fetal fibroblasts from the first and second trimester of gestation cultured in the presence of 5 and 20 ng/mL TGF β -1 with and without 10 μ M SB431542 for 18 h. The data are shown as mean $\pm$ S.E.M. of fold change in *FBN1–3* expression relative to the untreated control ($n=5$ ovaries from weeks 9–15 in the first trimester; $n=6$ ovaries from weeks 19–26 in the second trimester). Significantly different results for qRT-PCR were determined by one-way ANOVA with Dunnett's *post hoc* test. All values which were statistically different from the control are indicated by asterisk symbols in the graphs. * $P<0.05$, ** $P<0.01$, significant differences.

Figure 3 Expression of *FBN1–3* in bovine fetal ovarian tissue slices before and after 24-h culture. The data are shown as the mean $\pm$ S.E.M. of *FBN1–3* expression relative to 18S ($n=1$ ovary from 12 weeks of gestation and $n=3$ ovaries from weeks 16–18). Significantly different results for qRT-PCR were determined by unpaired *t*-tests. All values that were statistically different are indicated by asterisk symbols in the graphs. * $P<0.05$.

Figure 4 Expression levels of *FBN1–3* (pmol/nmol RPL32) in human fetal ovarian somatic cell/fibroblast cultures from different gestational ages from tissue digestion up to the eighth passage. T0 represents disaggregated ovarian tissue before culture and P0 represents adherent ovarian cells before the first passage. The different colored symbols represent cells from single ovaries at different gestational ages: (*) represents a 9-week ovary, (▲) represents a 15-week ovary, (●) represents a 16-week fetal ovary, and (■) represents a 17-week fetal ovary.

affected when these cells were treated with TGF β -1 (Fig. 2). However, it was observed that compared with the untreated control, there was a significant increase in *FBN1* expression in the TGF β -1-treated 19–26 week fibroblasts, with the higher TGF β -1 concentration causing a more significant increase in

Figure 5 Expression levels of *TGFB1–3*, *LTBP1–4*, *FBN1–2*, *TGFB1*, *AR*, *INHBA*, *HTRA1* and *BDNF* in primary human fetal ovarian fibroblast cultures in the presence or absence of 5 ng/mL TGF β -1, 100 ng/mL activin A and 10 μ M SB431542 for 24 h. The data shown are mean $\pm$ S.E.M. of target gene expression relative to the untreated control from 15–17 weeks gestation human fetal ovarian fibroblast cultures ($n=3$ ovaries). Significantly different results for qRT-PCR were determined by one-way ANOVA with Dunnett's *post hoc* test. All values which were statistically different from the control are indicated by asterisk symbols in the graphs. * $P<0.05$, ** $P<0.01$, significant differences.

FBN1 expression. This effect of TGF β -1 was prevented by the antagonist SB431542, which had no effect alone. TGF β -1 did not cause a significant effect on *FBN2* expression in the 9–15 week gestation cells (Fig. 2), but SB431542 caused a significant reduction in *FBN2* expression, with or without TGF β -1 (Fig. 2). In later gestation, TGF β -1 stimulated *FBN2* expression and SB431542 inhibited this stimulation, similarly to the effect on *FBN1* expression. None of the treatments significantly affected *FBN3* expression in fibroblast cultures of either gestational age (Fig. 2).

Expression of *FBN1–3* in bovine fetal ovarian tissue

We then measured expression levels of fibrillin genes in fetal ovarian tissue slices before (0h) and after culturing for 24 h ($n=1$ ovary from 12 weeks of gestation and $n=3$ ovaries from weeks 16–18). There were no significant differences ($P>0.05$) in *FBN1* and *FBN2* expression between the 0h ovarian tissue and the ovarian tissue cultured for 24 h (Fig. 3). However, we observed a significant decline in *FBN3* expression by 24 h.

Expression of *FBN1–3* in human fetal ovarian cells

The expression levels of *FBN1–3* were analyzed in disaggregated human fetal ovarian tissue ($n=4$ ovaries from 9–17 weeks of gestational age) before culture, in adherent ovarian fibroblasts before the first passage and up to the eighth cell passage. *FBN1* and *FBN2* expression increased in all cultures across passages (Fig. 4). *FBN3* was expressed higher in the disaggregated cells of a 9-week-old fetal ovary compared with later gestation fetal ovaries (Fig. 4). However, the ovarian cells of all fetal ovaries showed a dramatic decline in *FBN3* expression in culture and a loss of *FBN3* expression after the first passage.

TGF β -1, activin A and SB431542 treatment of human fetal ovarian cells

Human fetal ovarian fibroblasts ($n=3$ ovaries from 15–17 weeks gestation) were treated with 5 ng/mL TGF β -1, 100 ng/mL activin A and 10 μ M SB431542 separately. *TGFB1–3*, *LTBP1–4*, *FBN1–3*, *AR*, *INHBA*, *HTRA1* and *BDNF* expression levels were subsequently measured. SB431542 treatment significantly lowered *TGFB1*, *LTBP2*, *TGFB1*, *INHBA* and *BDNF* expression, whereas TGF β -1 treatment significantly reduced *AR* expression (Fig. 5). None of the treatments significantly affected *TGFB2–3*, *LTBP1*, *LTBP3–4*, *FBN1–2*, and *HTRA1* expression (Fig. 5). *FBN3* expression was not detectable in these cultures.

Discussion

In this study, we investigated the regulation of fibrillins and related TGF β s and latent TGF β binding proteins *in vitro* using bovine and human fetal ovaries under different culture conditions: monolayer culture, passaging of these monolayer cultures and culture of pieces of tissue. We initially carried out a screen for possible regulators of *FBN3*. The effects of TGF β and its pathway inhibitor SB431542 were examined in more detail and the effects on all fibrillins were examined. In humans, the effects of these and activin were also examined in detail. A consistent observation was that during culture, *FBN3* was downregulated and *FBN1* was upregulated, as occurs *in vivo* with increasing gestation (Hatzirodos *et al.* 2011).

To date, only one study has investigated the effects of TGF β signaling on the expression of fibrillin genes in fetal tissues. This study found that TGF β -1 increased *FBN1* and *FBN2* expression in murine fetal skin (Samuel *et al.* 2003). Since a murine model was used for that study, an examination of the expression of *FBN3* was not possible, as this gene is inactivated in mice (Corson *et al.* 2004). In adult fibroblasts, TGF β -1 was shown to increase *FBN1* and *FBN2* expression (Samuel *et al.* 2003), and the involvement of the TGF β superfamily is well characterized in ovarian follicle development (Knight & Glistler 2006). We therefore examined the effects of TGF β -1 on expression of the fibrillin genes. In the bovine study, we found that treatment with TGF β -1 caused a significant increase in *FBN1* and *FBN2* expression in the second trimester fibroblasts. These results suggest that in the bovine, TGF β -1 regulation of the expression of *FBN1* and *FBN2* only becomes active as development progresses. However, TGF β -1 treatment did not affect *FBN1* and *FBN2* expression in cultured human fetal ovarian fibroblasts at 15–17 weeks gestation. *FBN2* has different expression profiles in the bovine and human both during gestation and in the adult ovaries (Hatzirodos *et al.* 2011), suggesting differential regulation in these species. Furthermore, it appears that TGF β -1 regulates *FBN2* expression differently in the bovine and human later in gestation.

We also examined human fetal ovarian fibroblasts from later gestation when steroidogenic enzymes are expressed (Fowler *et al.* 2011). We observed that TGF β -1 treatment caused a significant decrease in the expression of the androgen receptor gene (*AR*). There are no previous studies investigating the effects of TGF β directly on *AR* expression. However, it is known that interaction of Smad3, a mediator of intracellular TGF β signaling, with the androgen receptor represses *AR*-mediated transcription, but the exact mechanisms of this repression are not well understood (Kang *et al.* 2001, Chipuk *et al.* 2002). Treatment of monkey kidney cells and human prostate cells with TGF β -1 caused a reduction in *AR*-mediated transcription as indicated by luciferase reporter activity in these cells (Hayes *et al.* 2001). The findings of our study suggest that TGF β signaling may repress *AR*-dependent transcription by inhibiting expression of the androgen receptor itself. On the other hand, we also observed significant reductions in the expression of the *TGFB1*, *LTBP2*, *TGFB1*, and *INHBA* genes when the human fetal ovarian fibroblasts were treated with the TGF β antagonist SB431542. SB431542 selectively inhibits TGF β type I receptors, activin-like receptor kinase 4, 5 and 7 (ALKs 4, 5 and 7) (Inman *et al.* 2002a). Therefore, ALK5 remains inactive (Callahan *et al.* 2002) and unable to phosphorylate Smads 2 and 3 (Callahan *et al.* 2002, Inman *et al.* 2002a) and the classical TGF β /smad pathway is disrupted (Heldin *et al.* 1997, Inman *et al.* 2002b, Derynck & Zhang 2003). TGF β -1 treatment causes a small and nonsignificant

increase in the expression of these genes; thus, the effect of SB431542 is likely to reflect antagonism of stimulation by endogenous TGF β signaling. Likewise, the reduction in *BDNF* expression with SB431542 treatment suggests that endogenous TGF β signaling is capable of stimulating *BDNF* expression in these cultured fibroblasts.

In culture of bovine fetal fibroblasts from the first trimester, SB431542 either alone or in combination with TGF β -1 caused a significant decrease in *FBN2* expression compared with the control even though TGF β -1 had no effect on these fibroblasts. Therefore, as with the human cell experiments, we speculate that SB431542 is inhibiting endogenous TGF β signaling via the TGF β type I and II receptors, which is stimulatory of *FBN2* expression. The TGF β superfamily ligands that bind to these receptors include TGF β s, activins, nodal and GDF8 (myostatin) (Heldin *et al.* 1997, Reissmann *et al.* 2001, Derynck & Zhang 2003, Rebbapragada *et al.* 2003). Currently, we have not identified which of these endogenous ligands are involved. On the other hand, in the second trimester bovine fibroblasts, the expression levels of *FBN1* and *FBN2* were similar to the control when SB431542 in combination with TGF β -1 was present in these cultures. Since we observed that TGF β -1 increased the expression of *FBN1* and *FBN2* in these fibroblasts, these observations suggest that SB431542 is alleviating the effects of exogenous TGF β -1, with no evidence of stimulation of the expression of these genes by endogenous TGF β . Overall, our observations show that *FBN1* and *FBN2* are differentially regulated in both the bovine and human ovary.

To date, there have not been any studies investigating the effect of activin A on the gene expression of fibrillins. However, previous studies have shown that activin A is capable of causing an increase in the proliferation of human lung fibroblasts (Heeren *et al.* 2015) as well as promoting proliferation of cultured rat renal interstitial fibroblasts and increasing the expression of type I collagen (Yamashita *et al.* 2004). We have observed that activin A did not affect the expression of *FBN1* or *FBN2* or the other TGF β -associated genes examined in our human samples. The levels of *FBN3* expression in the treated human fetal ovarian fibroblasts cultures were undetectable.

The fetal ovary consists of a mixture of cell types, and interactions between fibroblasts, GREL cells, pregranulosa/granulosa cells and germ cells might be required to maintain *FBN3* expression. The other cell types in the ovary may also be producing factors required by fibroblasts to stimulate *FBN3* expression. Thus, we carried out tissue culture experiments, but even a short-term culture (24h) of bovine fetal ovarian tissue sections, which represent a cross section of the three-dimensional ovarian structure containing all cell types and its extracellular matrix, showed a decline in the expression of *FBN3*. Similarly, we observed a drastic decline in *FBN3* expression but an increase in *FBN1* and *FBN2* expression in the cultured human fetal ovarian fibroblasts, consistent with development

of a more mature phenotype in culture. This indicates very stringent and possibly complex regulation of *FBN3* expression *in vivo*, which is not maintained *in vitro*, limiting our ability to study the expression of this gene.

A previous study showed that ovarian *FBN2* and *FBN3* are fetal fibrillins (Hatzirodos *et al.* 2011). *FBN3* is initially expressed highly and then begins to decline at the end of the first trimester and *FBN2* declines sometime between the fetal stages and adulthood at least in human (Hatzirodos *et al.* 2011). *FBN1* persists through fetal ovary development and is increased in the adult ovary (Hatzirodos *et al.* 2011) – it is an adult fibrillin. These data therefore imply that the three fibrillin genes have independent regulatory mechanisms to account for their different expression profiles in the bovine and human. This is also supported by the study of Davis *et al.* (2014), which found that there was little overlap in the transcription factor motifs present on the human *FBN3* promoter and those of *FBN1* and 2 promoters, suggesting that these genes are differentially regulated and differentially expressed (Davis *et al.* 2014).

In summary, *FBN3* expression is rapidly reduced in both cell and tissue culture, and was not maintained or stimulated by a range of growth factors. This study has also shown that in the bovine, there is differential regulation of *FBN1* and *FBN2* between the early and later stages of gestation, which is partially mediated through the signaling pathways involving either ALK 4, 5 or 7. TGF β regulates its own signaling both directly through TGF β expression and through regulation of expression of other binding proteins such as *LTBP2*. These data therefore demonstrate that the regulation of TGF β signaling appears to change during fetal ovarian development.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

Funding support for this research was obtained from the National Health and Medical Research Council of Australia, the University of Adelaide, the Clive and Vera Ramaciotti Foundation, the Wellcome Trust, the National Institute of Health and the Medical Research Council UK (G1100357).

Authors' contribution statement

N A B, K H, N H, W M B, M D H, H F I-R and R J R were responsible for planning the experiments on bovine samples, conducting cell culture and treatment experiments, RT-PCR, data analysis and interpretation as well as revising the manuscript. R A B and R A A conducted cell culture and treatment experiments on human samples, RT-PCR, data analysis and reviewed the manuscript.

Acknowledgments

We would like to thank Mrs Wendy Bonner for the collection of bovine fetal ovaries from the abattoir and Thomas Foods International, Murray Bridge, SA, for the supply of bovine fetal ovaries. We also thank Anne Saunderson and the staff of the Bruntsfield Suite, Royal Infirmary of Edinburgh for patient recruitment.

References

- Bayne RA, Kinnell HL, Coutts SM, He J, Childs AJ & Anderson RA 2015 GDF9 is transiently expressed in oocytes before follicle formation in the human fetal ovary and is regulated by a novel NOBOX transcript. *PLoS ONE* **10** e0119819. (doi:10.1371/journal.pone.0119819)
- Birchmeier C & Birchmeier W 1993 Molecular aspects of mesenchymal-epithelial interactions. *Annual Review of Cell and Developmental Biology* **9** 511–540. (doi:10.1146/annurev.cb.09.110193.002455)
- Callahan JF, Burgess JL, Fornwald JA, Gaster LM, Harling JD, Harrington FP, Heer J, Kwon C, Lehr R, Mathur A *et al.* 2002 Identification of novel inhibitors of the transforming growth factor beta1 (TGF-beta1) type 1 receptor (ALK5). *Journal of Medicinal Chemistry* **45** 999–1001. (doi:10.1021/jm010493y)
- Chaudhry SS, Cain SA, Morgan A, Dallas SL, Shuttleworth CA & Kielty CM 2007 Fibrillin-1 regulates the bioavailability of TGFbeta1. *Journal of Cell Biology* **176** 355–367. (doi:10.1083/jcb.200608167)
- Chen MM, Lam A, Abraham JA, Schreiner GF & Joly AH 2000 CTGF expression is induced by TGF- β in cardiac fibroblasts and cardiac myocytes: a potential role in heart fibrosis. *Journal of Molecular and Cellular Cardiology* **32** 1805–1819. (doi:10.1006/jmcc.2000.1215)
- Chipuk JE, Cornelius SC, Pultz NJ, Jorgensen JS, Bonham MJ, Kim SJ & Danielpour D 2002 The androgen receptor represses transforming growth factor-beta signaling through interaction with Smad3. *Journal of Biological Chemistry* **277** 1240–1248. (doi:10.1074/jbc.M108855200)
- Christner PJ & Ayitey S 2006 Extracellular matrix containing mutated fibrillin-1 (Fbn1) down regulates Col1a1, Col1a2, Col3a1, Col5a1, and Col5a2 mRNA levels in Tsk/+ and Tsk/Tsk embryonic fibroblasts. *Amino Acids* **30** 445–451. (doi:10.1007/s00726-005-0265-y)
- Corson GM, Charbonneau NL, Keene DR & Sakai LY 2004 Differential expression of fibrillin-3 adds to microfibril variety in human and avian, but not rodent, connective tissues. *Genomics* **83** 461–472. (doi:10.1016/j.ygeno.2003.08.023)
- Davis MR, Andersson R, Severin J, de Hoon M, Bertin N, Baillie JK, Kawaji H, Sandelin A, Forrest AR, Summers KM *et al.* 2014 Transcriptional profiling of the human fibrillin/LTBP gene family, key regulators of mesenchymal cell functions. *Molecular Genetics and Metabolism* **112** 73–83. (doi:10.1016/j.ymgme.2013.12.006)
- Derynck R & Zhang YE 2003 Smad-dependent and Smad-independent pathways in TGF-beta family signalling. *Nature* **425** 577–584. (doi:10.1038/nature02006)
- Fine A & Goldstein RH 1987 The effect of transforming growth factor-beta on cell proliferation and collagen formation by lung fibroblasts. *Journal of Biological Chemistry* **262** 3897–3902.
- Fowler PA, Anderson RA, Saunders PT, Kinnell H, Mason JI, Evans DB, Bhattacharya S, Flannigan S, Franks S, Monteiro A *et al.* 2011 Development of steroid signaling pathways during primordial follicle formation in the human fetal ovary. *Journal of Clinical Endocrinology & Metabolism* **96** 1754–1762. (doi:10.1210/jc.2010-2618)
- Hatzirodos N, Bayne RA, Irving-Rodgers HF, Hummitzsch K, Sabatier L, Lee S, Bonner W, Gibson MA, Rainey WE, Carr BR *et al.* 2011 Linkage of regulators of TGF-beta activity in the fetal ovary to polycystic ovary syndrome. *FASEB Journal* **25** 2256–2265. (doi:10.1096/fj.11-181099)
- Hayes SA, Zarnegar M, Sharma M, Yang F, Peehl DM, ten Dijke P & Sun Z 2001 SMAD3 represses androgen receptor-mediated transcription. *Cancer Research* **61** 2112–2118.
- Heeren AM, van Iperen L, Klootwijk DB, de Melo Bernardo A, Roost MS, Gomes Fernandes MM, Louwe LA, Hilders CG, Helmerhorst FM, van der Westerlaken LA *et al.* 2015 Development of the follicular basement membrane during human gametogenesis and early folliculogenesis. *BMC Developmental Biology* **15** 4. (doi:10.1186/s12861-015-0054-0)
- Heldin CH, Miyazono K & ten Dijke P 1997 TGF-beta signalling from cell membrane to nucleus through SMAD proteins. *Nature* **390** 465–471. (doi:10.1038/37284)
- Hughesdon PE 1982 Morphology and morphogenesis of the Stein-Leventhal ovary and of so-called "hyperthecosis". *Obstetrical and Gynecological Survey* **37** 59–77. (doi:10.1097/00006254-198202000-00001)
- Hummitzsch K, Irving-Rodgers HF, Hatzirodos N, Bonner W, Sabatier L, Reinhardt DP, Sado Y, Ninomiya Y, Wilhelm D & Rodgers RJ 2013 A new model of development of the mammalian ovary and follicles. *PLoS ONE* **8** e55578. (doi:10.1371/journal.pone.0055578)
- Hummitzsch K, Anderson RA, Wilhelm D, Wu J, Telfer EE, Russell DL, Robertson SA & Rodgers RJ 2015 Stem cells, progenitor cells, and lineage decisions in the ovary. *Endocrine Reviews* **36** 65–91. (doi:10.1210/er.2014-1079)
- Inman GJ, Nicolas FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, Laping NJ & Hill CS 2002a SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. *Molecular Pharmacology* **62** 65–74.
- Inman GJ, Nicolas FJ & Hill CS 2002b Nucleocytoplasmic shuttling of Smads 2, 3, and 4 permits sensing of TGF-beta receptor activity. *Molecular Cell* **10** 283–294. (doi:10.1016/S1097-2765(02)00585-3)
- Isogai Z, Ono RN, Ushiro S, Keene DR, Chen Y, Mazzieri R, Charbonneau NL, Reinhardt DP, Rifkin DB & Sakai LY 2003 Latent transforming growth factor beta-binding protein 1 interacts with fibrillin and is a microfibril-associated protein. *Journal of Biological Chemistry* **278** 2750–2757. (doi:10.1074/jbc.M209256200)
- Ito Y, Aten J, Bende RJ, Oemar BS, Rabelink TJ, Weening JJ & Goldschmeding R 1998 Expression of connective tissue growth factor in human renal fibrosis. *Kidney International* **53** 853–861. (doi:10.1111/j.1523-1755.1998.00820.x)
- Kang HY, Lin HK, Hu YC, Yeh S, Huang KE & Chang C 2001 From transforming growth factor-beta signaling to androgen action: identification of Smad3 as an androgen receptor coregulator in prostate cancer cells. *PNAS* **98** 3018–3023. (doi:10.1073/pnas.061305498)
- Knight PG & Glister C 2006 TGF-beta superfamily members and ovarian follicle development. *Reproduction* **132** 191–206. (doi:10.1530/rep.1.01074)
- Leask A & Abraham DJ 2004 TGF-beta signaling and the fibrotic response. *FASEB Journal* **18** 816–827. (doi:10.1096/fj.03-1273rev)
- Matti N, Irving-Rodgers HF, Hatzirodos N, Sullivan TR & Rodgers RJ 2010 Differential expression of foicimatrix and steroidogenic enzymes before size deviation during waves of follicular development in bovine ovarian follicles. *Molecular and Cellular Endocrinology* **321** 207–214. (doi:10.1016/j.mce.2010.02.019)
- Nelson VL, Legro RS, Strauss JF 3rd & McAllister JM 1999 Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. *Molecular Endocrinology* **13** 946–957. (doi:10.1210/mend.13.6.0311)
- Polla AS, Polla LL & Polla BS 2003 Iron as the malignant spirit in successful ageing. *Ageing Research Reviews* **2** 25–37. (doi:10.1016/S1568-1637(02)00048-X)
- Raja-Khan N, Urbanek M, Rodgers RJ & Legro RS 2014 The role of TGF-beta in polycystic ovary syndrome. *Reproductive Sciences* **21** 20–31. (doi:10.1177/1933719113485294)
- Ramirez F & Pereira L 1999 The fibrillins. *International Journal of Biochemistry and Cell Biology* **31** 255–259. (doi:10.1016/S1357-2725(98)00109-5)
- Rebbapragada A, Benchabane H, Wrana JL, Celeste AJ & Attisano L 2003 Myostatin signals through a transforming growth factor beta-like signaling pathway to block adipogenesis. *Molecular and Cellular Biology* **23** 7230–7242. (doi:10.1128/MCB.23.20.7230-7242.2003)
- Reissmann E, Jornvall H, Blokzijl A, Andersson O, Chang C, Minchiotti G, Persico MG, Ibanez CF & Brivanlou AH 2001 The orphan receptor ALK7 and the Activin receptor ALK4 mediate signaling by Nodal proteins during vertebrate development. *Genes & Development* **15** 2010–2022. (doi:10.1101/gad.201801)
- Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, Heine UI, Liotta LA, Falanga V, Kehrl JH *et al.* 1986 Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. *PNAS* **83** 4167–4171. (doi:10.1073/pnas.83.12.4167)

- Rock JR, Barkauskas CE, Cronic MJ, Xue Y, Harris JR, Liang J, Noble PW & Hogan BL** 2011 Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition. *PNAS* **108** E1475–E1483. (doi:10.1073/pnas.1117988108)
- Russe I** 1983 Oogenesis in cattle and sheep. *Bibliotheca Anatomica* **24** 77–92.
- Sabatier L, Miosge N, Hubmacher D, Lin G, Davis EC & Reinhardt DP** 2010 Fibrillin-3 expression in human development. *Matrix Biology* **30** 43–52. (doi:10.1016/j.matbio.2010.10.003)
- Saharinen J, Hyytiäinen M, Taipale J & Keski-Oja J** 1999 Latent transforming growth factor-beta binding proteins (LTBPs) – structural extracellular matrix proteins for targeting TGF-beta action. *Cytokine & Growth Factor Reviews* **10** 99–117. (doi:10.1016/S1359-6101(99)00010-6)
- Samuel CS, Sakai LY & Amento EP** 2003 Relaxin regulates fibrillin 2, but not fibrillin 1, mRNA and protein expression by human dermal fibroblasts and murine fetal skin. *Archives of Biochemistry and Biophysics* **411** 47–55. (doi:10.1016/S0003-9861(02)00710-5)
- Saxen L & Sariola H** 1987 Early organogenesis of the kidney. *Pediatric Nephrology* **1** 385–392. (doi:10.1007/BF00849241)
- Taipale J, Miyazono K, Heldin CH & Keski-Oja J** 1994 Latent transforming growth factor-beta 1 associates to fibroblast extracellular matrix via latent TGF-beta binding protein. *Journal of Cell Biology* **124** 171–181. (doi:10.1083/jcb.124.1.171)
- Urbanek M, Sam S, Legro RS & Dunaif A** 2007 Identification of a polycystic ovary syndrome susceptibility variant in fibrillin-3 and association with a metabolic phenotype. *Journal of Clinical Endocrinology & Metabolism* **92** 4191–4198. (doi:10.1210/jc.2007-0761)
- Varga J, Rosenbloom J & Jimenez SA** 1987 Transforming growth factor beta (TGF beta) causes a persistent increase in steady-state amounts of type I and type III collagen and fibronectin mRNAs in normal human dermal fibroblasts. *Biochemical Journal* **247** 597–604. (doi:10.1042/bj2470597)
- Wong T, McGrath JA & Navsaria H** 2007 The role of fibroblasts in tissue engineering and regeneration. *British Journal of Dermatology* **156** 1149–1155. (doi:10.1111/j.1365-2133.2007.07914.x)
- Yamashita S, Maeshima A, Kojima I & Nojima Y** 2004 Activin A is a potent activator of renal interstitial fibroblasts. *Journal of the American Society of Nephrology* **15** 91–101. (doi:10.1097/01.ASN.0000103225.68136.E6)
- Zilberberg L, Todorovic V, Dabovic B, Horiguchi M, Courousse T, Sakai LY & Rifkin DB** 2012 Specificity of latent TGF-beta binding protein (LTBP) incorporation into matrix: role of fibrillins and fibronectin. *Journal of Cellular Physiology* **227** 3828–3836. (doi:10.1002/jcp.v227.12)

Received 29 March 2016

First decision 30 April 2016

Revised manuscript received 4 May 2016

Accepted 23 May 2016